Viridian Therapeutics earnings were -$269.9M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest VRDN earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$79.7M, up 4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, VRDN reported annual earnings of -$269.9M, with 13.6% growth. The next VRDN earnings date is May 6, 2025.
Viridian Therapeutics Earnings Reports & History FAQ
What were Viridian Therapeutics's earnings last quarter?
On VRDN's earnings call on Invalid Date, Viridian Therapeutics (NASDAQ: VRDN) reported Q4 2024 earnings per share (EPS) of -$0.09, up 250% year over year. Total VRDN earnings for the quarter were -$79.73 million. In the same quarter last year, Viridian Therapeutics's earnings per share (EPS) was $0.06.
The next VRDN earnings call is Invalid Date. Add VRDN to your watchlist to be reminded of Viridian Therapeutics's next earnings date.
Is Viridian Therapeutics profitable or losing money?
As of the last Viridian Therapeutics earnings report, Viridian Therapeutics is currently losing money. Viridian Therapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$269.95 million, a 13.55% increase year over year.
What was VRDN's earnings growth in the past year?
As of Viridian Therapeutics's earnings date in Invalid Date, Viridian Therapeutics's earnings has grown year over year. VRDN earnings in the past year totalled -$269.95 million.
What are Viridian Therapeutics's earnings expectations?
The current EPS estimate for Viridian Therapeutics's earnings report in Invalid Date is -$1.10.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.